Medicines Assessment Advisory Committee
The Medicines Assessment Advisory Committee (MAAC) is a technical advisory committee established under section 8 of the Medicines Act 1981 to advise the Minister of Health on the risk-benefit profile of new medicines.
The Terms of Reference of the MAAC are as follows:
- To consider applications for the Minister's consent or provisional consent to the distribution of a new medicine referred to the Committee under section 22(2) of the Medicines Act 1981.
- To report to the Minister with a recommendation on the decision the Minister should make in respect of applications referred to the Committee under section 22(2) of the Medicines Act 1981.
- To annually review a sample of reports of the evaluation of applications for the Minister's consent or provisional consent to the distribution of new medicines and provide expert advice to Medsafe and the Minister on the quality of the risk-benefit assessments that have been completed.
The MAAC comprises up to 12 members, with experience in the practice of medicine, pharmaceutical chemistry and manufacturing and also a layperson representing consumer interests.
Members are appointed for a three year term, which may only be renewed once.
The MAAC is scheduled to meet three times a year (usually in March, June and September). Secretarial support is provided by Medsafe.
For further information on the date of the next meeting, or about the MAAC, contact the:
Secretary
Medicines Assessment Advisory Committee
Medsafe
P O Box 5013
Wellington 6145